Personnel changes at Alchemia
“The company has been diligently preparing for its transformation into a broader commercial organization and with our pivotal Phase 3 trial data read-out on the horizon for HA-irinotecan, along with a developing oncology pipeline, we are delighted to make this CEO appointment,” stated Santo J. Costa, Alchemia’s Incoming Chairman. “Thomas’ impressive background and strategic mindset makes him extremely qualified to lead Alchemia through this next stage of corporate growth. On behalf of the Board, I wish to thank Charlie for his service over the last year in helping guide our transition to products beyond fondaparinux.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.